Free Trial

Praxis Precision Medicines (PRAX) Stock Forecast & Price Target

Praxis Precision Medicines logo
$73.75 +0.07 (+0.10%)
(As of 11:59 AM ET)

Praxis Precision Medicines - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
8

Based on 9 Wall Street analysts who have issued ratings for Praxis Precision Medicines in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a hold rating, and 8 have given a buy rating for PRAX.

Consensus Price Target

$146.33
98.42% Upside
According to the 9 analysts' twelve-month price targets for Praxis Precision Medicines, the average price target is $146.33. The highest price target for PRAX is $270.00, while the lowest price target for PRAX is $48.00. The average price target represents a forecasted upside of 98.42% from the current price of $73.75.
Get the Latest News and Ratings for PRAX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Praxis Precision Medicines and its competitors.

Sign Up

PRAX Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$146.33$143.44$142.44$95.00
Forecasted Upside98.42% Upside98.54% Upside182.91% Upside460.47% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

PRAX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PRAX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Praxis Precision Medicines Stock vs. The Competition

TypePraxis Precision MedicinesMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside98.61% Upside26,931.56% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent PRAX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/7/2024Needham & Company LLC
2 of 5 stars
A. Fadia
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$151.00 ➝ $151.00+110.10%
11/7/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$120.00 ➝ $120.00+66.97%
10/31/2024Oppenheimer
3 of 5 stars
 Boost TargetOutperform ➝ Outperform$143.00 ➝ $163.00+132.36%
8/14/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Suneja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$155.00 ➝ $170.00+228.63%
8/14/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$40.00 ➝ $48.00-7.21%
7/1/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$270.00 ➝ $270.00+558.54%
Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

5/16/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$150.00 ➝ $150.00+233.48%
5/1/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$117.00+113.23%
3/26/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$75.00 ➝ $128.00+118.24%
3/3/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:22 PM ET.


PRAX Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Praxis Precision Medicines is $146.33, with a high forecast of $270.00 and a low forecast of $48.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There is currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRAX shares.

According to analysts, Praxis Precision Medicines's stock has a predicted upside of 98.42% based on their 12-month stock forecasts.

Praxis Precision Medicines has been rated by research analysts at HC Wainwright, Needham & Company LLC, and Oppenheimer in the past 90 days.

Analysts like Praxis Precision Medicines more than other "medical" companies. The consensus rating score for Praxis Precision Medicines is 2.89 while the average consensus rating score for "medical" companies is 2.80. Learn more on how PRAX compares to other companies.


This page (NASDAQ:PRAX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners